nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial.

ABSTRACT:

Purpose

The global Phase III MPACT trial demonstrated superior efficacy of nab-paclitaxel plus gemcitabine over gemcitabine alone as first-line treatment for metastatic pancreatic cancer. Region was a randomization stratification factor in the MPACT trial. This subgroup analysis of MPACT examined efficacy and safety of patients treated in Western Europe.

Patients and methods

Patients received nab-paclitaxel plus gemcitabine or gemcitabine alone as first-line treatment for metastatic pancreatic cancer as previously described. A total of 76 patients were included in this analysis (n=38 for each arm).

Results

Differences between the overall Western European cohort and the intention-to-treat population included lower percentages of male patients (46% and 58%

SUBMITTER: Tabernero J 

PROVIDER: S-EPMC5295788 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature